Shares of Celcuity Inc (NASDAQ:CELC) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price target of $36.00 for the company and are predicting that the company will post ($0.20) earnings per share for the current quarter, according to Zacks. Zacks has also given Celcuity an industry rank of 63 out of 256 based on the ratings given to related companies.
A number of research analysts have recently issued reports on CELC shares. Zacks Investment Research downgraded shares of Celcuity from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 30th. ValuEngine upgraded shares of Celcuity from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. Finally, HC Wainwright set a $36.00 price target on shares of Celcuity and gave the company a “buy” rating in a research note on Wednesday, May 8th.
Celcuity (NASDAQ:CELC) last issued its earnings results on Tuesday, May 7th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. As a group, sell-side analysts anticipate that Celcuity will post -0.81 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Celcuity by 32.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,483 shares of the company’s stock worth $445,000 after acquiring an additional 3,761 shares in the last quarter. ARS Investment Partners LLC grew its position in Celcuity by 48.2% during the fourth quarter. ARS Investment Partners LLC now owns 71,093 shares of the company’s stock valued at $1,706,000 after buying an additional 23,119 shares during the period. Vanguard Group Inc. grew its position in Celcuity by 59.8% during the third quarter. Vanguard Group Inc. now owns 259,900 shares of the company’s stock valued at $7,475,000 after buying an additional 97,266 shares during the period. Kessler Investment Group LLC grew its position in Celcuity by 46.3% during the first quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock valued at $154,000 after buying an additional 2,222 shares during the period. Finally, Geode Capital Management LLC grew its position in Celcuity by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock valued at $840,000 after buying an additional 2,930 shares during the period. Hedge funds and other institutional investors own 22.05% of the company’s stock.
Celcuity Company Profile
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Recommended Story: Return On Assets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.